Tumor-Derived Microvesicles Induce Proangiogenic Phenotype in Endothelial Cells via Endocytosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Increasing evidence indicates that tumor endothelial cells (TEC) differ from normal endothelial cells (NEC). Our previous reports also showed that TEC were different from NEC. For example, TEC have chromosomal abnormality and proangiogenic properties such as high motility and proliferative activity. However, the mechanism by which TEC acquire a specific character remains unclear. To investigate this mechanism, we focused on tumor-derived microvesicles (TMV). Recent studies have shown that TMV contain numerous types of bioactive molecules and affect normal stromal cells in the tumor microenvironment. However, most of the functional mechanisms of TMV remain unclear. METHODOLOGY/PRINCIPAL FINDINGS: Here we showed that TMV isolated from tumor cells were taken up by NEC through endocytosis. In addition, we found that TMV promoted random motility and tube formation through the activation of the phosphoinositide 3-kinase/Akt pathway in NEC. Moreover, the effects induced by TMV were inhibited by the endocytosis inhibitor dynasore. Our results indicate that TMV could confer proangiogenic properties to NEC partly via endocytosis. CONCLUSION: We for the first time showed that endocytosis of TMV contributes to tumor angiogenesis. These findings offer new insights into cancer therapies and the crosstalk between tumor and endothelial cells mediated by TMV in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.107821 · Cited by 1,934 · cited 2×
“A previous report indicates the possibility that protein and/or nucleic acids (mRNAs, miRNA) are packaged into MVs and can be taken up by cells, acting as biomolecules [14,20,28,29].”
BackgroundShedding microvesicles: artefacts no more
Cocucci, E., Racchetti, G., & Meldolesi, J. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.11.003 · Cited by 1,742
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006) · Leukemia · doi:10.1038/sj.leu.2404296 · Cited by 1,340 · cited 1×
“MVs have recently attracted attention among researchers of immune response and embryo development, playing a role in cellto-cell communication [13].”
BackgroundWysoczynski, M., & Ratajczak, M. Z. (2009) · International Journal of Cancer · doi:10.1002/ijc.24479 · Cited by 216 · cited 1×
“There are several reports that MVs secreted from malignant tumor cells (tumorderived MVs: TMV) affect surrounding normal cells [23,24].”
Background
Cited by
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Li, X., Corbett, A. L., Taatizadeh, E., Tasnim, N., Little, J. P., Garnis, C., Daugaard, M., Guns, E., Hoorfar, M., & Li, I. T. S. (2019) · APL Bioengineering · doi:10.1063/1.5087122 · Cited by 564
Exosomes: The next generation of endogenous nanomaterials for advanced drug delivery and therapy
Liao, W., Du, Y., Zhang, C., Pan, F., Yao, Y., Zhang, T., & Peng, Q. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.045 · Cited by 411
Extracellular vesicles as biomarkers and therapeutic targets for cancer
Urabe, F., Kosaka, N., Ito, K., Kimura, T., Egawa, S., & Ochiya, T. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00280.2019 · Cited by 397
Nanbo, A., Kawanishi, E., Yoshida, R., & Yoshiyama, H. (2013) · Journal of Virology · doi:10.1128/jvi.01310-13 · Cited by 355
Metadata
- Authors
- Kawamoto, T., Ohga, N., Akiyama, K., Hirata, N., Kitahara, S., Maishi, N., Osawa, T., Yamamoto, K., Kondoh, M., Shindoh, M., Hida, Y., & Hida, K.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-30
- Volume
- 7
- Issue
- 3
- Pages
- e34045
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2051512394
- Cited by
- 101
- References
- 4
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.